ArticleJournal of translational medicine2025
AAV-mediated STC-1 expression mitigates neuroinflammation and preserves visual function in degenerative retinopathy.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Letter to editor: AAV-mediated STC-1 expression mitigates neuroinflammation and preserves visual function in degenerative retinopathy.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRetinal degeneration (RD) is a chronic retinopathy that characterized by the progressive photoreceptor apoptosis and visual impairments. However, due to the complicated pathogenesis of RD, there is no effective treatment at present. This study intends to verify the therapeutic effect and mechanism of stanniocalcin-1 (STC-1) in the sodium iodate (NaIO
methodsThe pAAV2/8-Stc1 vector was established and delivered into the vitreous cavity of RD mouse model. Subsequently, these treated mice were subjected to a series of functional and morphological assay.
resultsPervasive neuroinflammation reaction and oxidative stress occurred in the retinas of RD model. Intravitreal injection of pAAV2/8-Stc1 vector enabled the stable STC-1 expression in the retinas. AAV-mediated STC-1 overexpression could preserve the retinal structure and enhance the photoreceptor survival effectively. Fundus photography showed the distribution of retinal vessel was clear, and the severity of lesions was relieved. Particularly, these morphological benefits could yield significant improvements in visual functionality, as evidenced by both behavioral tests and multifocal electroretinogram (mf-ERG) evaluations. Mechanism study showed that STC-1 alleviated the oxidative stress, inhibited the neuroglia activation, and mitigated the release of pro-inflammatory cytokines through CX3CL1/CX3CR1/NF-κB axis.
conclusionsThis research unveils a robust correlation between the photoreceptor vitality and the STC-1 expression in RD model. The AAV mediated STC-1 over-expression can be developed into a promising therapeutic approach for degenerative retinopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.